Back to Agenda
Compliance, Potential Financial Implications, and Impact of New Safety Measures
Session Chair(s)
John Whitebrook, PHD
Partner, Deloitte MCS Ltd., United Kingdom
Good Pharmacovigilance Practices (GVP): The Real Impacts and Consequences
Learning Objective : Discuss how safety measures can increase productivity while containing costs; Identify how to involve, and collaborate with, external groups such as patients; Discuss the impacts of Good Pharmacovigilance Practices (GVP) on industry; Gain insights into pragmatic approaches to deal with GVP in the real world.
Speaker(s)
John Whitebrook, PHD
Partner, Deloitte MCS Ltd., United Kingdom
Good Pharmacovigilance Practices (GVP): The Real Impacts and Consequences
Peter Honig, MD, MPH, FACP
, Advisor and Board Member, United States
Industry Perspective
Tatsuo Kurokawa, DIAFellow, PHD
Director General, The Japan Biosimilar Association, Japan
Financial Implications of Drug Safety Measures and a Potential Remedy
Have an account?